Welcome to our dedicated page for Mannkind Corporation news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind Corporation stock.
MannKind Corporation (Nasdaq: MNKD) is a leading biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative inhaled therapeutic products for patients with serious unmet medical needs. The company focuses on treating diseases such as diabetes, pulmonary arterial hypertension, and nontuberculous mycobacterial (NTM) lung disease.
Their flagship product, Afrezza, is an ultra-rapid-acting inhaled insulin designed to improve glycemic control in adults with diabetes. This product features a dry powder formulation of human insulin delivered via a small, portable inhaler.
MannKind's latest advancements include the initiation of a Phase 3 trial for Clofazimine Inhalation Suspension aimed at treating refractory NTM lung disease. The trial, named ICoN-1, will evaluate the efficacy and safety of the drug when added to standard therapy. This initiative is a response to the increasing global prevalence of NTM lung infections, which pose significant health risks and complications for patients.
Additionally, MannKind is progressing with a Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). This study will assess the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers.
The company's technological prowess is underlined by its proprietary Technosphere® dry-powder technology, which facilitates rapid and effective delivery of medicines to the deep lung. This technology, combined with their inhalation devices, is used to develop new treatments that can either act locally in the lungs or enter the systemic circulation, depending on the medical need.
In a strategic partnership, MannKind has in-licensed Pulmatrix's iSPERSE™ technology to enhance their formulation capabilities. This collaboration also includes exchanging MannKind's Cricket® inhaler technology to aid in the development of inhaled treatments for migraine and other neurological diseases.
Financially, MannKind continues to invest in R&D to expand its product pipeline and enhance its technological platforms. The company’s partnerships, such as the recent agreement with Pulmatrix, are also set to strengthen MannKind's market position in the biopharmaceutical landscape.
With a dedicated team and a robust pipeline, MannKind Corporation remains at the forefront of developing effective inhaled therapies, striving to improve patient outcomes and quality of life.
MannKind Corporation (Nasdaq: MNKD) is set to release its 2022 third quarter financial results and year-to-date performance on November 8, 2022, at 9:00 AM ET.
CEO Michael Castagna and CFO Steven Binder will discuss the results during a conference call, accessible via the company's website. MannKind focuses on innovative therapies for endocrine and lung diseases, utilizing advanced inhalation technologies. For further details, visit their official site.
MannKind Corporation (Nasdaq: MNKD) announced that its CEO, Michael Castagna, PharmD, will participate in the Lytham Partners Fall 2022 Investor Conference on September 28-29, 2022. The company's webcast presentation will be available on September 28 at 9:00 am ET via its website. Additionally, management will hold virtual one-on-one meetings during the event. MannKind focuses on developing innovative therapeutic products for endocrine and orphan lung diseases, particularly utilizing advanced dry-powder formulations and inhalation devices.
MannKind Corporation (Nasdaq: MNKD) announced the successful completion of a Phase 1 study on clofazimine inhalation suspension (MNKD-101) for treating nontuberculous mycobacterial (NTM) lung disease. The study indicated that the inhalation solution was well tolerated, with no serious adverse events or QT prolongation. The FDA has designated MNKD-101 as an orphan lung and qualified infectious disease product, addressing a high unmet medical need. MannKind plans discussions with the FDA regarding the findings and the ongoing clinical program.
MannKind Corporation (Nasdaq: MNKD) announced CEO Michael Castagna will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 12:00 PM ET in New York. The company focuses on developing innovative therapeutic products for endocrine and orphan lung diseases. Interested parties can access the live webcast and replay for 14 days via the company’s website. MannKind aims to improve the lives of patients using their advanced inhalation devices and formulations for conditions like diabetes and pulmonary arterial hypertension.
MannKind Corporation (Nasdaq: MNKD) reported a total revenue of $18.9 million for Q2 2022, a 28% increase year-over-year, driven by Afrezza net revenue of $10.6 million. The FDA approved Tyvaso DPI, contributing to revenue recognition. However, collaborations revenue decreased by $7.4 million compared to Q2 2021. The net loss decreased to $29.0 million, or $0.11 per share, from $35.5 million, aided by improved gross profit margins. Expenses rose due to heightened promotional efforts for Afrezza and V-Go.
MannKind Corporation (Nasdaq: MNKD) will announce its 2022 second-quarter financial results on August 9, 2022, at 5:00 PM Eastern Time. CEO Michael Castagna and CFO Steven Binder will lead a conference call to discuss these results and the company's updates. MannKind focuses on developing innovative therapies, particularly for conditions like diabetes and pulmonary arterial hypertension, leveraging its specialized dry-powder delivery technology. Investors can access the live call through the company’s website for detailed insights on performance and strategy.
MannKind Corporation (Nasdaq: MNKD) announced its participation in the BTIG Biotechnology Conference on August 8-9, 2022. CEO Michael Castagna and CFO Steven Binder will engage in one-on-one meetings during this event, aimed at institutional investors.
BTIG specializes in various financial services and hosts client events across multiple sectors. MannKind is known for its innovative products for endocrine and lung diseases, notably Afrezza (insulin human) Inhalation Powder, the only inhaled ultra-rapid-acting insulin approved in the U.S. This participation highlights MannKind’s ongoing commitment to advancing its therapeutic portfolio.
MannKind Corporation (Nasdaq: MNKD) is set to showcase its innovative diabetes solutions at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans from June 3-7, 2022. Highlighting its commitment to diabetes care, the company will feature products like Afrezza® and V-Go®. MannKind will host a booth (#1019) to engage healthcare professionals and present an abstract on Technosphere® Insulin. Additionally, a Product Theater event on ultra-rapid inhaled insulin will take place on June 4 at 4:30 p.m. (ET) with featured experts.
MannKind Corporation (Nasdaq: MNKD) announced FDA approval for United Therapeutics' Tyvaso DPI (treprostinil) inhalation powder, marking it as the first dry powder treatment for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Manufacturing is commencing at MannKind's Connecticut facility, with availability expected in June 2022. This marks the second FDA approval utilizing MannKind’s Technosphere inhalation technology, promoting convenience and improved health management for patients.
MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will ring the opening bell at Nasdaq on May 23, 2022, at 9:30 am ET. The ceremony is part of a promotional event to highlight the company's focus on inhaled therapeutic products for endocrine and orphan lung diseases. MannKind's flagship product, Afrezza, is the only FDA-approved inhaled ultra-rapid acting mealtime insulin in the U.S. and is also available in Brazil through its partner, Biomm SA. This event reflects the company’s commitment to bringing innovative treatments to market.
FAQ
What is the current stock price of Mannkind Corporation (MNKD)?
What is the market cap of Mannkind Corporation (MNKD)?
What is MannKind Corporation's primary focus?
What is Afrezza?
What recent advancements has MannKind made?
What is Technosphere<sup>®</sup> technology?
What is the significance of the iSPERSE<sup>™</sup> technology partnership?
What diseases does MannKind target with its products?
Where can I find more information about MannKind Corporation?
Is MNKD-101 approved for use?
What is the significance of the ICoN-1 trial?